. 2018 Nov 5;7(11):e10006. doi: 10.2196/10006

Table 2.

Schedule of participants enrollment and baseline assessment, 2017-2018.

Test	Screening^a	Baseline visit^b
Informed consent process	X
Review inclusion/exclusion criteria to determine study eligibility, including smoking status and iQOS use	X
Review medical history	X
Provide study requirements handout (explain study/visit requirements)	X
Pregnancy test	X	X
Stanford 25 comprehensive clinical assessment		X
Spirometry (FVC^c, FEV^d, FEV1^e, FEV1/ FVC, FEF^f 25-75, MEF^g), bronchodilation test using salbutamol		X
CAT^h		X
6MWTⁱ		X
Short form-12 Quality of Life questionnaire		X
ECG^j		X
Body mass index		X
Smoking status and exposures		X
Comprehensive physical assessment Stanford 25		X
Previous COPD^k exacerbations based on use of inhaled steroids, antibiotics, inhaled bronchodilators, steroids		X
Previous COPD exacerbations based on health care visits (office visits, admissions to emergency department or hospital)		X
Previous COPD severe exacerbations based on emergency department admission or hospitalizations		X
Laboratory testing for blood cholesterol level, CBC^l (25 parameters); HDL^m, LDLⁿ, triglycerides, C-reactive protein, fibrinogen, glucose, glycosylated hemoglobin		X
Biomarker testing for sRAGE^o, ICAM1^p, and CCL20^q		X
Lung computer tomography		X

^aMonths –3 to 3.

^bMonths 0 to 3.

^cFVC: forced vital capacity.

^dFEV: forced expiratory volume.

^eFEV1: forced expiratory volume in 1 second.

^fFEF: forced expiratory flow.

^gMEF: maximum expiratory flow.

^hCAT: COPD Assessment Test.

ⁱ6MWT: 6-Minute Walk Test.

^jECG: electrocardiogram.

^kCOPD: chronic obstructive pulmonary disease.

^lCBC: complete blood count.

^mHDL: high-density lipoproteins.

ⁿLDL: low-density lipoproteins.

^osRAGE:advanced glycosylation end-product receptor.

^pICAM1: intercellular adhesion molecule 1.

^qCCL20: macrophage inhibitory protein 3a.